Pegsunercept

Pegsunercept is a biopharmaceutical that was under development for the treatment of rheumatoid arthritis. It is a pegylated form of a soluble tumor necrosis factor receptor (TNFR) that acts as a TNF inhibitor.

History

Pegsunercept was developed by Amgen, a multinational biopharmaceutical company. The drug was in Phase III clinical trials for the treatment of rheumatoid arthritis but development was discontinued.

Mechanism of Action

Pegsunercept works by inhibiting the action of tumor necrosis factor (TNF), a substance in the body that causes inflammation. It does this by binding to TNF and preventing it from activating TNF receptors. This reduces inflammation and helps to slow down the progression of diseases that are caused by an overactive immune response, such as rheumatoid arthritis.

Clinical Trials

Pegsunercept underwent Phase III clinical trials for the treatment of rheumatoid arthritis. However, the development of the drug was discontinued for unknown reasons.

See Also

• Biopharmaceutical
• Rheumatoid arthritis
• Tumor necrosis factor
• TNF inhibitor
• Amgen

Pegsunercept Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski